High levels of cathepsin S and cystatin C in patients with fibromyalgia syndrome

Basit Öğe Kaydı
dc.authoridZONTUL, Cemile/0000-0002-1436-5145
dc.authoridTAS, Ayca/0000-0002-7132-1325
dc.authoridKARADAG, Ahmet/0000-0002-5284-2256
dc.contributor.authorKocak, Ibrahim
dc.contributor.authorHizmetli, Sami
dc.contributor.authorTas, Ayca
dc.contributor.authorKaradag, Ahmet
dc.contributor.authorZontul, Cemile
dc.contributor.authorSilig, Yavuz
dc.date.accessioned2024-10-26T18:07:21Z
dc.date.available2024-10-26T18:07:21Z
dc.date.issued2020
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjectives Although the etiopathogenesis of fibromyalgia syndrome (FM) is not yet clear, central sensitization is thought to be responsible for the pathogenesis of FM. The aim of this study was to compare the serum cathepsin S (CatS) and cystatin C (CysC) levels between patients with FM and healthy control subjects. Methods This study was conducted in the Physical Medicine and Rehabilitation Clinic between January 2019 and October 2019. The study included 145 FM patients newly diagnosed with primary FM according to the 2010 American College of Rheumatology criteria and 129 healthy volunteers. The age, gender, and body mass index (BMI) of the participants were recorded. Venous blood samples were collected from both groups for the measurement of the levels of serum CatS and CysC. The functional status of FM patients was evaluated using the Fibromyalgia Impact Questionnaire (FIQ). Results No statistically significant difference was determined between the patient and control groups in terms of age, gender, and BMI (P > .05). A comparison of the serum CatS and CysC levels of the FM and control groups revealed a statistically significant difference (P = .001). No correlation was determined between FIQ and serum CatS and CysC levels (P > .05). Conclusion Serum CatS and CysC levels were found to be higher in FM patients. However, there was no correlation between the functional status of FM patients and serum CatS and CysC levels. These results can be of guidance for further clinical studies of the etiopathogenesis and treatment of FM.
dc.description.sponsorship[T-839]
dc.description.sponsorshipThis study was supported by the scientific research project fund of our university (project no: T-839).
dc.identifier.doi10.1111/1756-185X.13840
dc.identifier.endpage969
dc.identifier.issn1756-1841
dc.identifier.issn1756-185X
dc.identifier.issue7
dc.identifier.pmid32307906
dc.identifier.scopus2-s2.0-85083658592
dc.identifier.scopusqualityQ3
dc.identifier.startpage966
dc.identifier.urihttps://doi.org/10.1111/1756-185X.13840
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29464
dc.identifier.volume23
dc.identifier.wosWOS:000526585100001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal of Rheumatic Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectcathepsin S
dc.subjectcystatin C
dc.subjectfibromyalgia
dc.subjectpain
dc.titleHigh levels of cathepsin S and cystatin C in patients with fibromyalgia syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu